Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus
Aims. To evaluate carotid intima-media thickness (cIMT) and biomarkers of the osteoprotegerin/receptor activator of nuclear factor-κB ligand (OPG/RANKL) system in type 1 diabetes (T1DM) children and adolescents and controls. Subjects and Methods. Fifty six T1DM patients (mean ± SD age: 12.0 ± 2.7 ye...
Saved in:
Main Authors: | Irene Lambrinoudaki, Emmanouil Tsouvalas, Marina Vakaki, George Kaparos, Kimon Stamatelopoulos, Areti Augoulea, Paraskevi Pliatsika, Andreas Alexandrou, Maria Creatsa, Kyriaki Karavanaki |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2013/102120 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune Activation, Immunosenescence, and Osteoprotegerin as Markers of Endothelial Dysfunction in Subclinical HIV-Associated Atherosclerosis
by: Alessandra D’Abramo, et al.
Published: (2014-01-01) -
Osteoprotegerin in Cardiometabolic Disorders
by: C. Pérez de Ciriza, et al.
Published: (2015-01-01) -
Advanced mutant receptor activator of nuclear factor kappa‐Β ligand development with low affinity for osteoprotegerin
by: Yuria Jang, et al.
Published: (2025-01-01) -
Previous Gestational Diabetes Mellitus and Markers of Cardiovascular Risk
by: Nikolaos Vrachnis, et al.
Published: (2012-01-01) -
Association of blood pressure and left ventricular mass with subclinical coronary atherosclerosis
by: Weiting Huang, et al.
Published: (2025-02-01)